Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jonathan Temte MD, PhD
Jonathan Temte MD, PhD Advisory Board
Dipesh Navsaria MPH, MSLIS, MD
Dipesh Navsaria MPH, MSLIS, MD Advisory Board
Tricia Elliott MD, FAAFP
Tricia C. Elliott MD, FAAFP Associate Editor
See All Experts
story of the week
Published in Primary Care and
2 other channels

Journal Scan / Research · September 25, 2015

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

The New England Journal of Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Silvio Inzucchi MD

Peter Lin MD, CCFP

Benjamin Scirica MD

The New England Journal of Medicine
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
N. Engl. J. Med 2015 Sep 17;[EPub Ahead of Print], B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, S Hantel, M Mattheus, T Devins, OE Johansen, HJ Woerle, UC Broedl, SE Inzucchi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated